Gene Variants Influence Weight Loss and Side Effects of GLP-1 Drugs

A genome-wide association study has identified specific genetic variants that influence how individuals respond to GLP-1 receptor agonist medications used for weight management, including semaglutide and tirzepatide.

The research, published in Nature, suggests that variations in drug target genes contribute to the significant differences seen between patients regarding weight loss efficacy and the occurrence of side effects.

Genetic Predictors of Weight Loss

Researchers conducted the study using data from 27,885 people who underwent GLP-1 receptor agonist therapy. The analysis focused on self-reported weight loss and treatment-related side effects to determine the genetic basis of patient variability.

The study identified a missense variant in the GLP1R gene that is significantly associated with increased medication efficacy. Specifically, the findings indicate that each copy of the effect allele is associated with an expected additional weight loss of 0.76 kg.

Links to Side Effects

Beyond weight loss, the study examined the genetic drivers of common side effects, such as nausea and vomiting. The results linked variations in two specific genes to these adverse reactions: GLP1R and GIPR.

The association with the GIPR gene was found to be restricted to patients using tirzepatide. This distinction is relevant because tirzepatide is a dual agonist that targets both the GLP-1 and GIP receptors, whereas other GLP-1 medications may target only one.

Implications for Precision Medicine

The ability to identify these genetic markers allows for the development of a broader model of medication response. This model can be used to stratify patients based on their predicted efficacy and their risk of experiencing side effects.

By utilizing this genetic evidence, healthcare providers may eventually move toward precision medicine approaches in the treatment of obesity. This would involve tailoring the choice of medication or dosage to a patient’s genetic profile to maximize weight loss while minimizing adverse effects.

The study provides direct evidence that variation in the genes encoding the drug targets themselves is a primary driver of why different people experience vastly different outcomes when using the same class of medication.